Yüklüyor......
Novel Single Inhibitor of HDAC6/8 and Dual Inhibitor of PI3K/HDAC6 as Potential Alternative Treatments for Prostate Cancer
Background: Prostate cancer is the second most frequently diagnosed malignancy worldwide. Here, the cytotoxic and antimetastatic effects of a new HDAC6/8 inhibitor, LASSBio-1911, and a new dual-PI3K/HDAC6 inhibitor, LASSBio-2208, were evaluated against PC3 prostate cancer cell line. Methods: A MTT a...
Kaydedildi:
| Yayımlandı: | Pharmaceuticals (Basel) |
|---|---|
| Asıl Yazarlar: | , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
MDPI
2021
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8143108/ https://ncbi.nlm.nih.gov/pubmed/33919077 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ph14050387 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|